General inclusion and exclusion criteria for clinical trial participation
We are currently conducting studies for patients with moderate-to-severe asthma that is not well controlled despite regular maintenance treatment.
| ✓ Inclusion criteria | ✗ Exclusion criteria |
|---|---|
| ✓ Age 12–70 years (depending on the study) | ✗ Severe uncontrolled comorbidities (cardiac, metabolic, psychiatric) |
| ✓ Asthma diagnosis for at least 6–12 months | ✗ Exacerbation or respiratory infection in the last 4–6 weeks |
| ✓ Documented reversible airway obstruction (bronchodilator response) | ✗ Active smoker or smoking history >10 pack-years |
| ✓ Stable dose of ICS ± LABA (maintenance therapy) for at least 3 months | ✗ Pregnancy or breastfeeding |
| ✓ FEV₁ ≥ 30–80% predicted (varies by study) | ✗ Other significant pulmonary disease (COPD, cystic fibrosis, pulmonary fibrosis) |
| ✓ At least 1 exacerbation requiring systemic steroids in the past 12 months | ✗ Current or recent use of other biologic therapy for asthma |
| ✓ Signed informed consent | ✗ Known allergy to study drug components |
We are conducting studies for patients with moderate to very severe COPD who experience frequent exacerbations despite regular inhaler use.
| ✓ Inclusion criteria | ✗ Exclusion criteria |
|---|---|
| ✓ Age 40–80 years | ✗ Asthma as primary diagnosis |
| ✓ COPD diagnosis for at least 1 year (per GOLD criteria) | ✗ Exacerbation or respiratory infection in the last 4 weeks |
| ✓ Smoking history ≥ 10 pack-years (current or former) | ✗ Active pulmonary rehabilitation (<4 weeks) |
| ✓ FEV₁/FVC < 0.70 and FEV₁ 20–80% predicted | ✗ Continuous oxygen therapy >12 hours/day |
| ✓ On stable triple (ICS+LABA+LAMA) or dual inhaled therapy for ≥3–6 months | ✗ Active or past malignancy |
| ✓ ≥ 2 moderate or ≥ 1 severe exacerbation in the past 12 months | ✗ Unstable cardiovascular disease |
| ✓ CAT score ≥ 10–15 (symptomatic COPD) | ✗ Other significant pulmonary disease |
We are participating in a Phase III study (AIRTIVITY™) of a novel oral tablet (cathepsin C inhibitor) for patients with bronchiectasis who experience recurrent flare-ups.
| ✓ Inclusion criteria | ✗ Exclusion criteria |
|---|---|
| ✓ Age ≥ 12 years (adolescents must weigh ≥35 kg) | ✗ Cystic fibrosis |
| ✓ CT-confirmed bronchiectasis | ✗ Active mycobacterial (NTM) infection or tuberculosis |
| ✓ Chronic sputum production (able to produce a sputum sample) | ✗ Lung surgery or transplantation in the past 12 months |
| ✓ ≥ 2 pulmonary exacerbations requiring antibiotics in the past 12 months | ✗ Pregnancy or breastfeeding |
| ✓ Post-BD FEV₁ ≥ 30% predicted | ✗ Allergic bronchopulmonary aspergillosis (ABPA) |
| ✓ Signed informed consent | ✗ Continuous oxygen therapy >12 hours/day |
Specific criteria vary by protocol. Only the study doctor can determine your eligibility after a thorough assessment. Contact us — we are happy to help.